# FDA recall D-0992-2022

> **Teva Pharmaceuticals USA Inc** · Class I · drug recall initiated 2022-05-11.

## Product

Anagrelide Capsules USP, 0.5 mg,  100-count bottles, Rx Only, Manufactured in India For: TEVA PHARMACEUTICALS USA, Inc., North Wales, PA 19454. NDC 0172-5241-60.

## Reason for recall

Failed Dissolution Specifications- Low Out-Of-Specification results obtained during stability testing.

## Distribution

Distributed Nationwide in the USA

## Key facts

- **Recall number:** D-0992-2022
- **Recalling firm:** Teva Pharmaceuticals USA Inc
- **Classification:** Class I
- **Product type:** drug
- **Status:** Terminated
- **Initiation date:** 2022-05-11
- **Report date:** 2022-06-08
- **Termination date:** 2024-02-26

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** Parsippany, NJ, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0992-2022

## Citation

> AI Analytics. FDA recall D-0992-2022. Retrieved 2026-06-25 from https://api.ai-analytics.org/recall/D-0992-2022. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*